The Online Investor

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Mon., Jan. 24, 11:32 AM

Slide #12. Intra-Cellular Therapies, Inc. Secondary Offering

Company: Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
Date announced: 1/3/2022
Shares Offered: 9,523,810
Date of Pricing: 1/4/2022
Price Per Share: $42.00
Secondary Offering Details: Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it has commenced an underwritten public offering of $400 million of shares of its common stock. In connection with the offering, Intra-Cellular Therapies intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares in the offering will be sold by Intra-Cellular Therapies. -updated 1/4- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced the pricing of its previously announced underwritten public offering of 9,523,810 shares of its common stock at a public offering price of $42.00 per share. All of the shares in the offering will be sold by Intra-Cellular Therapies, with gross proceeds to Intra-Cellular Therapies expected to be $400.0 million before deducting underwriting discounts and commissions and offering expenses. Intra-Cellular Therapies has granted the underwriters a 30-day option to purchase up to an additional 1,428,571 shares on the same terms and conditions. The offering is expected to close on January 7, 2022, subject to the satisfaction of customary closing conditions.

Intra-Cellular Therapies is a biopharmaceutical company focused on the discovery, clinical development and commercialization of small molecule drugs that address medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system. Co.'s product candidate, CAPLYTA™ (lumateperone) has been approved by the U.S. Food and Drug Administration for the treatment of schizophrenia in adults. Co. is developing ITI-1284 for the treatment of behavioral disturbances in patients with dementia, the treatment of dementia-related psychosis and for the treatment of certain depressive disorders in the elderly.

ITCI SEC Filing Email Alerts Service

Open the ITCI Page at The Online Investor »

Company Name: 
Intra-Cellular Therapies Inc
Website: 
www.intracellulartherapies.com
Sector: 
Drugs & Pharmaceuticals
Number of ETFs Holding ITCI: 
32
Total Market Value Held by ETFs: 
$399.02M
Total Market Capitalization: 
$3.17B
% of Market Cap. Held by ETFs: 
12.60%
 

Open the ITCI Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree ITCI Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Strong Buy (3.71 out of 4)
59th percentile
(ranked higher than approx. 59% of all stocks covered)

Analysts' Target Price:
ITCI Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.